# EP Edge Journal Watch Special Edition: VOLT IDE One-Year Results in Context: ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-Per-AF & U.S. PFA Pivotal Trials

Page: https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials
Text version: https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials.md
Podcast: [EP Edge Journal Watch](https://stenobird.com/podcast/ep-edge-journal-watch-7561379)
Published: 2026-02-06T19:19:46+00:00
Episode link: https://share.transistor.fm/s/fd4a1bb4
Audio file: https://media.transistor.fm/fd4a1bb4/0c45f488.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials
Duration seconds: 566

## Resource

Pulsed field ablation (PFA) has rapidly reshaped atrial fibrillation ablation, but true clinical validation depends on durable one-year outcomes, not early feasibility or acute safety alone . In this EP Edge Journal Watch Special Edition , Dr. Niraj Sharma delivers a comprehensive, system-level analysis of the Abbott VOLT IDE one-year data , now completing the 12-month efficacy and safety landscape across major U.S. PFA platforms. This episode critically reviews and contextualizes results from the VOLT IDE trial alongside other pivotal and near-pivotal studies, including ADVENT , ADVANTAGE-AF , AdmIRE , SPHERE-9 first-in-human , and SPHERE-Per-AF . The discussion spans paroxysmal, persistent, and advanced AF populations , with attention to how ablation strategy (PVI-only vs adjunctive lesions), patient risk profile, and post-ablation monitoring intensity influence reported outcomes. Key themes include one-year efficacy versus composite effectiveness , freedom from atrial arrhythmias, repeat procedures, and major safety endpoints such as stroke, tamponade, and esophageal injury. Rather than ranking technologies, this episode emphasizes methodology, trial design, and clinical context , explaining why efficacy signals differ across studies and how these data should be interpreted in everyday electrophysiology practice. For additional references, detailed tables, graphics, and deeper comparative analysis , visit the LinkedIn EP Edge newsletter and Substack at ephedge.substack.com . If you have suggestions or concerns, you can reach Dr. Sharma at ephedgecast@gmail.com

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.